Antibodies in Drug Discovery

Date: Monday, 6 March 2017 - Tuesday, 7 March 2017
Location: Wellcome Genome Campus Conference Centre, Cambridge, UK

Keynote Speakers

Sally Ward
Professor, Texas A&M Health Science Center

Overview

SELECTBIO is pleased to announce Antibodies in Drug Discovery 2017, will be held on 6 - 7 March 2017 in Cambridge, UK.

The event will form part of the multi-track conference, Advances in Drug Discovery, and will run alongside three additional tracks: Epigenetics in Drug Discovery, Academic Drug Discovery and Stem Cells in Drug Discovery. Attendees will benefit from unrestricted access to all four conference tracks.

Attracting researchers, academics and industry professionals working in antibody research, this track will fully explore the latest developments in the design and engineering of antibodies in relation to the burgeoning field of biotherapeutics. Topics to be addressed include, engineering challenges and techniques, new technologies and business hurdles when developing antibodies, the latest developments in autoimmune and infectious disease research.

If you work in antibody drug discovery research you will benefit from the expert knowledge of academic and industry leaders who are pushing the boundaries of antibody discovery, whilst networking with the technology providers who are enabling them to do so.

SELECTBIO is offering a limited number of student bursaries at this event. Find out more

Agenda Topics

Antibodies for New Targets
Antibody Drug Conjugates (ADCs)
Antibody Screening
Cancer - Immunology
Humanised Single Domain Antibodies for Research and Therapeutic Applications
Monoclonal Antibodies
Targeting Ion Channels with Biologics

Sponsorship and Exhibition Opportunities

Exhibition Team,
exhibitors@selectbio.com
+44 (0) 1206 501654

Confirmed Speakers to date

Dolores Cahill, Professor, University College Dublin
Mark Chiu, Principal Research Scientist, Janssen R&D Llc
Suzanne Cohen, , MedImmune
Nick Devoogdt, Professor, Free University Brussels (VUB)
Ernesto Freire, Professor, Johns Hopkins University
André Frenzel, , Leibniz Universität Hannover
Frank Gesellchen, Senior Scientist, Sphere Fluidics
Andrew Green, Senior Drug Discovery Specialist, Discoverx
Claire Hatty, Application Specialist, NanoTemper
Simon Hufton, Section Head Molecular Immunology, National Institute for Biological Standard and Control (NIBSC)
Michael Hust, Professor, Technical University of Braunschweig
Shamir Jacobino, Researcher, University Medical Center Utrecht
Leo James, , MRC Laboratory of Molecular Biology
Roman Kischel, Principal Scientist, Amgen Research
Daniel Lightwood, Director, UCB Pharma
Craig Malcolm, Strategic Collaborations Manager, Promega UK Ltd
Christoph Merten, Principal Investigator, European Molecular Biology Laboratory
Serge Muyldermans, Professor, Vrije Universiteit
Sai Reddy, Assistant Professor, ETH Zurich
Christian Schoneich, Professor, University of Kansas
Eugene Zhukovsky, Chief Scientific Officer, Biomunex Pharmaceuticals